Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenue $ 141 $ 33 $ 292 $ 62
Operating expenses:        
Cost of revenue - sales 65 32 135 72
Cost of revenue - impairment of inventory 186   186  
Research and development 1,187 1,160 4,040 4,359
Sales and marketing 725 509 2,196 2,954
General and administrative 2,315 2,155 7,104 7,432
Total costs and expenses 4,478 3,856 13,661 14,817
Operating loss (4,337) (3,823) (13,369) (14,755)
Gain (loss) on change in estimated fair value of contingent royalty obligation (35) (3) (152) 248
Loss on extinguishment of debt (237)   (237)  
Finance expense, net (216) (117) (450) (348)
Other income 5   5  
Foreign currency loss (4) (1) (12) (4)
Net loss (4,824) (3,938) (14,215) (14,859)
Deemed dividends from warrant issuance (6,145)
Net loss attributable to common shareholders $ (4,824) $ (3,938) $ (20,360) $ (14,859)
Basic and diluted loss per common share:        
Net loss (in Dollars per share) $ (0.1) $ (0.13) $ (0.31) $ (0.51)
Net loss attributable to common shareholders (in Dollars per share) $ (0.1) $ (0.13) $ (0.44) $ (0.51)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 48,241,188 30,422,265 46,419,643 29,366,154